Will new treatment regimen drive a more effective immune response for people with HER2-positive metastatic breast cancer?

A randomized clinical trial is studying whether the addition of the immunotherapy drug, atezolizumab (Tecentriq®), to the standard treatment regimen will improve outcomes for people with HER2-positive metastatic breast cancer (MBC). Researchers are looking to see if the addition of this drug will also help improve the immune response.